Do analysts recommend ORGS or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGS or NCNA more profitable?

NuCana has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% NuCana N/A -153.61% -116.03%

Do analysts prefer ORGS or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Creative Medical Technology 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, OBSV or ORGS?

Orgenesis has higher revenue and earnings than ObsEva. Orgenesis is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Orgenesis $662K 3.51 -$55.36M -$11.51 N/A

Is OBSV or ORGS more profitable?

ObsEva has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Orgenesis -3,827.81% N/A -130.18%

Do analysts recommend ORGS or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 349.78%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EGRX or ORGS more profitable?

Eagle Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Eagle Pharmaceuticals N/A N/A N/A Orgenesis -3,827.81% N/A -130.18%

Orgenesis (ORGS) Competitors

$0.45 -0.05 (-9.09%)

As of 09:34 AM Eastern

Compare

ORGS vs. NCNA, CELZ, OBSV, ERNA, and EGRX

Should you buy Orgenesis stock or one of its competitors? MarketBeat compares Orgenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orgenesis include NuCana (NCNA), Creative Medical Technology (CELZ), ObsEva (OBSV), Ernexa Therapeutics (ERNA), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry.

How does Orgenesis compare to NuCana?

Orgenesis (NASDAQ:ORGS) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

NuCana has lower revenue, but higher earnings than Orgenesis. NuCana is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.51	-$55.36M	-$11.51	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

In the previous week, NuCana had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for NuCana and 0 mentions for Orgenesis. NuCana's average media sentiment score of 1.89 beat Orgenesis' score of 0.00 indicating that NuCana is being referred to more favorably in the news media.

Company	Overall Sentiment
Orgenesis	Neutral
NuCana	Very Positive

Orgenesis has a beta of 2.89, meaning that its stock price is 189% more volatile than the broader market. Comparatively, NuCana has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 44.0% of NuCana shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by company insiders. Comparatively, 31.2% of NuCana shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NuCana has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
NuCana	N/A	-153.61%	-116.03%

Summary

NuCana beats Orgenesis on 9 of the 13 factors compared between the two stocks.

How does Orgenesis compare to Creative Medical Technology?

Orgenesis (NASDAQ:ORGS) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

In the previous week, Creative Medical Technology had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Creative Medical Technology and 0 mentions for Orgenesis. Creative Medical Technology's average media sentiment score of 1.92 beat Orgenesis' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Orgenesis	Neutral
Creative Medical Technology	Very Positive

Creative Medical Technology has lower revenue, but higher earnings than Orgenesis. Creative Medical Technology is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.51	-$55.36M	-$11.51	N/A
Creative Medical Technology	$10K	846.19	-$5.99M	-$2.14	N/A

Orgenesis has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.84, meaning that its share price is 84% more volatile than the broader market.

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 1.9% of Orgenesis shares are held by insiders. Comparatively, 1.7% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Creative Medical Technology	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Creative Medical Technology has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Creative Medical Technology	N/A	-88.38%	-84.71%

Summary

Creative Medical Technology beats Orgenesis on 8 of the 14 factors compared between the two stocks.

How does Orgenesis compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

17.5% of ObsEva shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 14.4% of ObsEva shares are held by company insiders. Comparatively, 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Orgenesis	Neutral

ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Orgenesis has a beta of 2.89, meaning that its share price is 189% more volatile than the broader market.

ObsEva has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Orgenesis	-3,827.81%	N/A	-130.18%

Orgenesis has higher revenue and earnings than ObsEva. Orgenesis is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Orgenesis	$662K	3.51	-$55.36M	-$11.51	N/A

Summary

ObsEva and Orgenesis tied by winning 5 of the 10 factors compared between the two stocks.

How does Orgenesis compare to Ernexa Therapeutics?

Orgenesis (NASDAQ:ORGS) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Ernexa Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Ernexa Therapeutics	N/A	-263.74%	-151.16%

Orgenesis has a beta of 2.89, suggesting that its share price is 189% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.49, suggesting that its share price is 149% more volatile than the broader market.

Ernexa Therapeutics has lower revenue, but higher earnings than Orgenesis. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.51	-$55.36M	-$11.51	N/A
Ernexa Therapeutics	N/A	N/A	-$14.08M	-$26.20	N/A

In the previous week, Ernexa Therapeutics had 5 more articles in the media than Orgenesis. MarketBeat recorded 5 mentions for Ernexa Therapeutics and 0 mentions for Orgenesis. Ernexa Therapeutics' average media sentiment score of 0.57 beat Orgenesis' score of 0.00 indicating that Ernexa Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Orgenesis	Neutral
Ernexa Therapeutics	Positive

22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 1.9% of Orgenesis shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 349.78%. Given Ernexa Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ernexa Therapeutics beats Orgenesis on 8 of the 15 factors compared between the two stocks.

How does Orgenesis compare to Eagle Pharmaceuticals?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Eagle Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Orgenesis	-3,827.81%	N/A	-130.18%

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Orgenesis has a beta of 2.89, indicating that its share price is 189% more volatile than the broader market.

Eagle Pharmaceuticals has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.03	$35.64M	$1.18	0.52
Orgenesis	$662K	3.51	-$55.36M	-$11.51	N/A

In the previous week, Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
Orgenesis	Neutral

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats Orgenesis on 8 of the 10 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGS vs. The Competition

Export

Metric	Orgenesis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.33M	$960.50M	$6.50B	$12.36B
Dividend Yield	N/A	4.84%	2.67%	5.67%
P/E Ratio	-0.04	1.43	23.99	24.69
Price / Sales	3.51	125.05	538.03	166.93
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	-0.07	8.01	10.47	6.82
Net Income	-$55.36M	-$4.88M	$3.56B	$337.45M
7 Day Performance	-9.09%	3.69%	1.21%	2.49%
1 Month Performance	N/A	2.56%	2.14%	4.37%
1 Year Performance	-76.92%	49.45%	26.24%	32.80%

Orgenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGS Orgenesis	N/A	$0.45 -9.1%	N/A	-74.6%	$2.33M	$662K	N/A	150	Gap Down
NCNA NuCana	1.4688 of 5 stars	$1.95 -1.0%	N/A	-91.5%	$8.20M	N/A	N/A	30	Positive News
CELZ Creative Medical Technology	0.7562 of 5 stars	$2.11 -3.2%	N/A	+0.6%	$8.06M	$10K	N/A	5	Positive News
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
ERNA Ernexa Therapeutics	3.682 of 5 stars	$6.34 -6.8%	$30.00 +373.2%	-89.3%	$7.93M	$580K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGS) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orgenesis (ORGS) Competitors

ORGS vs. NCNA, CELZ, OBSV, ERNA, and EGRX

How does Orgenesis compare to NuCana?

Summary

How does Orgenesis compare to Creative Medical Technology?

Summary

How does Orgenesis compare to ObsEva?

Summary

How does Orgenesis compare to Ernexa Therapeutics?

Summary

How does Orgenesis compare to Eagle Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orgenesis (ORGS) Competitors

ORGS vs. NCNA, CELZ, OBSV, ERNA, and EGRX

How does Orgenesis compare to NuCana?

Which has stronger earnings and valuation, ORGS or NCNA?

Does the media favor ORGS or NCNA?

Which has more risk and volatility, ORGS or NCNA?

Do analysts recommend ORGS or NCNA?

Do institutionals and insiders believe in ORGS or NCNA?

Is ORGS or NCNA more profitable?

Summary

How does Orgenesis compare to Creative Medical Technology?

Does the media refer more to ORGS or CELZ?

Which has preferable earnings and valuation, ORGS or CELZ?

Which has more volatility & risk, ORGS or CELZ?

Do insiders and institutionals believe in ORGS or CELZ?

Do analysts prefer ORGS or CELZ?

Is ORGS or CELZ more profitable?

Summary

How does Orgenesis compare to ObsEva?

Do insiders & institutionals believe in OBSV or ORGS?

Does the media refer more to OBSV or ORGS?

Which has more risk and volatility, OBSV or ORGS?

Is OBSV or ORGS more profitable?

Which has stronger earnings and valuation, OBSV or ORGS?

Summary

How does Orgenesis compare to Ernexa Therapeutics?

Is ORGS or ERNA more profitable?

Which has more risk and volatility, ORGS or ERNA?

Which has better valuation and earnings, ORGS or ERNA?

Does the media prefer ORGS or ERNA?

Do institutionals and insiders have more ownership in ORGS or ERNA?

Do analysts recommend ORGS or ERNA?

Summary

How does Orgenesis compare to Eagle Pharmaceuticals?

Is EGRX or ORGS more profitable?

Which has more risk & volatility, EGRX or ORGS?

Which has preferable earnings & valuation, EGRX or ORGS?

Does the media prefer EGRX or ORGS?

Do institutionals & insiders hold more shares of EGRX or ORGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools